# Traveler-based Genomic Surveillance Program

Canonical: https://abierto.us/opportunities/rfp75d30124r72969

- Solicitation number: RFP75D30124R72969
- Notice type: Combined synopsis and solicitation
- Status: Closed. Deadline was August 9, 2024 at 11:00 AM EDT
- Department: Department of Health and Human Services
- Agency: Centers for Disease Control and Prevention
- Contracting office: CDC Office of Acquisition Services (75D301)
- NAICS: 541380 Testing Laboratories and Services
- Product or service code: R408 Program Management/Support Services
- First posted: July 9, 2024
- Last posted: August 26, 2024
- SAM.gov: https://sam.gov/workspace/contract/opp/9e8a9f6af51a49f3824498a87bc21ec1/view

## Description

Revised Solicitation and Questions and Responses Updated posted 7/31/2024. For the solicitation CLIN 2004 period of performance was updated to 8/26/2025 - 8/25/2026. Section F was also updated. Questions and Responses posted 7/18/2024. Solicitation Revision #1 7/10/2024 - Section A (1)(d) language that inidcated a small business set-aside is removed. See updated solicitation document.

The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance. The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) .

TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC.

Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.

The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance. The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) .

TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC.

Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.

## Publications

- July 9, 2024: Combined synopsis and solicitation, due August 9, 2024 at 11:00 AM EDT. Notice 6353e216f12f4f7f9eb838242f376bc1. https://sam.gov/workspace/contract/opp/6353e216f12f4f7f9eb838242f376bc1/view
- July 10, 2024: Combined synopsis and solicitation, due August 9, 2024 at 11:00 AM EDT. Notice e1fc600bb9e140b38bed12cc05fae240. https://sam.gov/workspace/contract/opp/e1fc600bb9e140b38bed12cc05fae240/view
- July 18, 2024: Combined synopsis and solicitation, due August 9, 2024 at 11:00 AM EDT. Notice ccb6d1f5f3874c8ab5888fb46fc355cb. https://sam.gov/workspace/contract/opp/ccb6d1f5f3874c8ab5888fb46fc355cb/view
- July 31, 2024: Combined synopsis and solicitation, due August 9, 2024 at 11:00 AM EDT. Notice 9339b123af324c09b6b5e538dbe3d495. https://sam.gov/workspace/contract/opp/9339b123af324c09b6b5e538dbe3d495/view
- July 31, 2024: Combined synopsis and solicitation, due August 9, 2024 at 11:00 AM EDT. Notice d6a3e5d92ae94034aed11cbb545d05c1. https://sam.gov/workspace/contract/opp/d6a3e5d92ae94034aed11cbb545d05c1/view
- August 26, 2024: Combined synopsis and solicitation, due August 9, 2024 at 11:00 AM EDT. Notice 9e8a9f6af51a49f3824498a87bc21ec1. https://sam.gov/workspace/contract/opp/9e8a9f6af51a49f3824498a87bc21ec1/view

## Points of contact

- Howard D. Bish, uwo8@cdc.gov, 4044981312

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/rfp75d30124r72969.